Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D3.164 - Safety and Efficacy of VIT against Wasp Venom in Patients Older than 60 Years
- D3.165 - Consistent long term benefit of allergen immunotherapy in patients with allergic rhinitis
- D3.166 - The mental health of adolescent patients with cat allergy improves with rapid dosing of depigmented cat allergoids
- D3.167 - Allergoids: Characterising Identity Pre- and Post- Modification Using Compendial and Novel Methods
- D3.169 - Advantage of IgG reactivity testing for the analytical quantification of allergoids
- D3.172 - Аllergen-specific immunotherapy in patients with allergic rhinitis
- D3.173 - Nationwide pivotal registry study on house dust mite immunotherapy in allergic rhinitis patients with or without asthma in China (NAVIGATOR)
- D3.174 - Comparative analysis of extracts from Cupressus arizonica and Juniperus ashei pollens
- D3.175 - Tumor Necrosis Factor Receptor 2 (TNFR2) is crucial for the efficacy of Allergen-Specific Immunotherapy in a Pre-clinical Murine Model
- D3.176 - The value of TNF and IL1RN genes in predicting the clinical efficacy of SCIT in children with asthma
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download